Dan Conway, MD just returned from San Francisco and CROI where he made a poster presentation of a study, Prevalence of Congenital Anomalies in Infants with in Utero Exposure to Antiretrovirals: IMPAACT P1025. The IMPAACT group found that the rate of congenital anomalies, especially cardiovascular ones, was higher in children enrolled in this study. P1025 was a study that enrolled over 1300 pregnant women and followed the outcomes of both them and their infants. Efavirenz (Sustiva TM), a known teratogen, was the only antiretroviral found to be linked in a statistically significant way to anomalies. Dr. Conway reports that the conference was interesting and informative.
No comments:
Post a Comment